Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.2). Positive Phase 3 HAELO topline results for lonvo-z in hereditary angioedema.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Positive Phase 3 HAELO topline results for lonvo-z in hereditary angioedema
- Potential global first for in vivo gene editing, strengthening Intellia’s clinical and commercial positioning
- Press release and Phase 3 presentation furnished as Exhibits 99.1 and 99.2
- April 27, 2026 disclosure provides investors access to efficacy and safety details in referenced exhibits
Item 8.01 · Other Events
- Phase 3 HAELO met its primary endpoint, with lonvo-z reducing attacks 87% versus placebo over six months
- Mean monthly attack rate 0.26 with lonvo-z versus 2.10 with placebo, p<0.0001
- 62% of lonvo-z patients were attack-free and therapy-free versus 11% on placebo
- Favorable safety profile: all treatment-emergent adverse events mild or moderate, with no serious events
- Rolling U.S. BLA submission initiated; completion targeted for second half of 2026 and potential launch first half of 2027
Item EX-99.1 · Exhibit EX-99.2
- Phase 3 HAELO met primary and key secondary endpoints, materially de-risking lonvo-z’s regulatory path
- One-time 50 mg dose reduced attacks 87% versus placebo, with monthly attack rates of 0.26 versus 2.10
- 62% became attack-free and therapy-free for six months versus 11% on placebo, supporting potential treatment differentiation
- Favorable safety profile: all reported adverse events mild or moderate, with no serious adverse events in the lonvo-z arm
- Rolling FDA BLA submission initiated, with potential U.S. launch targeted for the first half of 2027 if approved
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.